What Arcturus Therapeutics Holdings Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sassine Andy | Chief Financial Officer | Aug 15 | Open-market buy · P | +1,238 | $16.56 | +$20.5K | 221,764 |
| Chivukula Pad | Chief Scientific Officer & COO | Oct 15 | Open-market sale · S | −12,000 | $20.76 | −$249K | 435,334 |
| Holmes Edward W | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 3,131 |
| Farrell Peter C | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 55,741 |
| Marquet Magda | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 3,131 |
| Barlow James F | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 13,131 |
| Marantz Jing L. | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 3,131 |
| Markels John | Director | Jun 14 | Exercise / conversion · M | +3,131 | — | — | 3,131 |
| Sassine Andy | Chief Financial Officer | Jun 12 | Open-market sale · S | −50,000 | $32.03 | −$1.6M | 220,526 |
| Chivukula Pad | Chief Scientific Officer & COO | Jun 05 | Open-market sale · S | −114 | $45.00 | −$5.13K | 447,334 |
| Chivukula Pad | Chief Scientific Officer & COO | Jun 03 | Open-market sale · S | −26,000 | $40.01 | −$1.04M | 447,448 |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 25 | Open-market sale · S | −17,435 | $35.02 | −$611K | 473,448 |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 19 | Open-market sale · S | −8,565 | $35.01 | −$300K | 490,883 |
| Chivukula Pad | Chief Scientific Officer & COO | Nov 01 | Open-market sale · S | −5,000 | $18.72 | −$93.6K | 499,448 |
| Chivukula Pad | Chief Scientific Officer & COO | Oct 02 | Open-market sale · S | −5,000 | $25.61 | −$128K | 504,448 |
| Chivukula Pad | Chief Scientific Officer & COO | Sep 01 | Open-market sale · S | −5,000 | $31.45 | −$157K | 509,448 |
| Sassine Andy | Chief Financial Officer | Aug 15 | Grant / award · A | +1,223 | $17.37 | +$21.2K | 270,526 |
| Chivukula Pad | Chief Scientific Officer & COO | Aug 01 | Open-market sale · S | −5,000 | $34.91 | −$175K | 514,448 |
| Chivukula Pad | Chief Scientific Officer & COO | Jul 14 | Open-market sale · S | −25,000 | $35.01 | −$875K | 519,448 |
| Kummerfeld Keith C | See Remarks | Jul 14 | Disclosed 10b5-1 sale · S | −6,968 | $35.00 | −$244K | 950 |
Loading...
